Adjudicated US Private

Theranos: Fabricated Revenue Projections and Fake Blood Analyzer Demos

Elizabeth Holmes and Sunny Balwani deceived investors with fake DOD contract claims, false revenues, and proprietary analyzer demos run on commercial machines.

CASE PROFILE & BENCHMARKS
  • Target Issuer: Theranos, Inc. (US).
  • Fraud Period: January 1, 2018 to December 31, 2020.
  • Reported Overstatement: $700.0M.
  • Total Fines & Penalties: $500K.
  • Maximum Incarceration: No prison sentence.
  • Independent Auditor: PricewaterhouseCoopers LLP.
  • Primary Schemes: misleading non gaap and kpis.
  • Enforcement Status: ADJUDICATED (admitted).
OVERSTATEMENT $700.0M USD reported
TOTAL PENALTIES $500K Civil & disgorgement
PRISON TIME None No prison sentence
FIRST ACTION September 20, 2020 Initial proceeding
DETECTION METHOD Regulatory Enforcement & Forensic Audit Discovery source
PRIMARY REGULATOR U.S. Securities and Exchange Commission US

FORENSIC ACCOUNTING AUTOPSY & MECHANICS

COMPREHENSIVE MULTI-PHASE INVESTIGATION
Forensic Dimension Investigative Finding & Evidentiary Record
Executive Motive & Pressure Founded by Elizabeth Holmes in 2003, Theranos raised over $900M from high-profile investors at a $9B valuation by claiming its 'Edison' and 'miniLab' devices could run hundreds of clinical blood tests from a single finger-prick drop.
Auditor Blind Spots & Breakdown As a private company, Theranos operated without an independent public-company PCAOB audit for most of its growth phase, utilizing strict NDAs, compartmentalized labs, and selective investor demonstrations to prevent technical and financial due diligence.
Detection Catalyst & Unraveling In October 2015, Wall Street Journal investigative reporter John Carreyrou exposed that Theranos ran almost all blood tests on commercial Siemens machines rather than its own Edison box. CMS regulators subsequently revoked Theranos's lab license, leading to SEC fraud charges and criminal wire fraud convictions for Holmes and Balwani.
Screening & Prevention Takeaway Private Valuation Governance & Unaudited Projections: Extreme secrecy, refusal to publish peer-reviewed validation, and lack of independent audited financial statements at multi-billion-dollar private valuations are critical red flags for institutional due diligence.
Statutory Violations & Charges
18 U.S.C. Section 1343 & 1349 (Wire Fraud & Conspiracy to Commit Wire Fraud) Securities Act Section 17(a) & Exchange Act Section 10(b) CMS Clinical Laboratory Improvement Amendments (CLIA) License Revocation

STEP-BY-STEP SCHEME EXECUTION MECHANICS

4 PHASES
Phase Execution Step & General Ledger Mechanics
Step 01 1. Theranos's proprietary finger-prick devices failed internal accuracy benchmarks on most assays, so lab staff secretly diluted finger-prick samples and ran them on modified commercial Siemens analyzers.
Step 02 2. Holmes and COO Sunny Balwani presented investors with fabricated financial models projecting $100M in 2014 revenue and $1B in 2015 revenue when actual commercial lab revenue was near zero.
Step 03 3. Marketing decks displayed logos of major pharmaceutical companies (Pfizer, GlaxoSmithKline) as active validators even though those firms had declined partnerships.
Step 04 4. Executives falsely claimed the US military was actively deploying Theranos devices on medevac helicopters in Afghanistan.

FORENSIC JOURNAL ENTRIES & T-ACCOUNT DISTORTIONS

GENERAL LEDGER TRANSACTIONS
Period Debit (+) Account Debit ($) Credit (-) Account Credit ($) Forensic Intent & Financial Statement Distortion
2013-2015 (Investor Private Placement Misrepresentation) Cash (Series C-1 / C-2 Venture Proceeds) $700.0M Preferred Equity Capital (Raised on False Revenue Models) $700.0M
Intent: Raise $700M+ from private investors using fabricated $100M-$1B revenue projections and fake DoD contract claims.
Distortion: Values private shares at $9B despite less than $100,000 in genuine commercial diagnostic revenue.
Taxonomy Applicable Scheme Classifications
Correlated Schemes

CHARGED RESPONDENTS & OUTCOMES

1 NAMED PARTIES
Respondent Role Disposition & Judicial Outcome Prison Civil Penalty O&D Bar
Theranos, Inc. ISSUER Enforcement order and financial sanctions imposed. None $500K No

RED FLAGS OBSERVED PRIOR TO DISCOVERY

1 EARLY WARNING INDICATORS
Red Flag Indicator Period Observed Observed Forensic Anomaly Diagnostic View
CASH FLOW TO NET INCOME DIVERGENCE 2018 Operating cash flow severely diverged from reported earnings Inspect Metric →

ENFORCEMENT ACTIONS & PRIMARY DOCKETS

PRIMARY SOURCE CITATIONS
Filing Date Type & Docket ID Enforcement Order & Regulatory Findings Disposition Primary Record
September 20, 2020
aaer
ENF-2018-theranos
Enforcement Action: Theranos: Fabricated Revenue Projections and Fake Blood Analyzer Demos
Elizabeth Holmes and Sunny Balwani deceived investors with fake DOD contract claims, false revenues, and proprietary analyzer demos run on commercial machines.
Securities & Corporate Law Compliance
Source: U.S. Securities and Exchange Commission: Accounting and Auditing Enforcement Releases (AAER) • Official Jurisdiction: US
admitted Docket Record ↗

TIMELINE OF EVENTS

2 CHRONOLOGICAL MILESTONES
Date Event Category Chronological Forensic Milestone
June 1, 2018 MISSTATEMENT Material accounting irregularities commenced.
September 20, 2020 ENFORCEMENT Regulators commenced formal proceedings.